Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04126681 | A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase | PHASE2 | COMPLETED | 144 | — | — | Oct 21, 2019 | Aug 1, 2024 | Mar 3, 2025 | 22 | China, China +20 |
| NCT03882281 | Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid Leukemia | PHASE1 | COMPLETED | 12 | — | — | Mar 25, 2019 | Nov 16, 2019 | Jan 22, 2020 | 1 | China |
| Name | Type | Description |
|---|---|---|
| HQP1351 | DRUG | HQP1351 is a new, bioavailable inhibitor against BCRABLWT and a broad spectrum of BCR-ABL mutants including BCR-ABLT315I |
| Hydroxyurea or Interferon-based therapy | DRUG | Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines. |
| Homoharringtonine | DRUG | Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines. |
| Imatinib, Dasatinib or Nilotinib | DRUG | Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines. |